Kornimate/medical-research-clean huggingface dataset:
patterned functional electrical stimulation (fes) ergometry of arm and shoulder in individuals with spinal cord injury

Conditions: Spinal Cord Injury

Summary: to determine whether functional electrical stimulation (fes) promotes neurological and physical recovery in patients with spinal cord injury (sci). the researchers will investigate the extent of functional recovery in patients with spinal cord injury who receive functional electrical stimulation in the upper extremities compared with patients who do not receive fes.

a randomized, controlled, single-blinded, in-subject controlled (a-b type) trial will be performed in patients with sci receiving an upper extremities non-fes assisted exercise protocol compared with patients receiving upper extremities ergometry in combination with fes. neurological and functional outcome measures will be obtained at baseline (time 0), after 1st 4 months of intervention (4 months), after 1 month washout (5 months),after 2nd 4 months intervention (9 months), and 3 month after completing the last intervention (12 months).

Eligibility criteria:
inclusion criteria: * male, female, age 18-55, all ethnic groups * spinal cord injury, traumatic and non-traumatic * c1-c6 neurological level * asia class a-b * chronic injury \> 12 months and \< 20 years from the injury * no upper-extremity electrical stimulation in the previous 4 weeks * subjects are medically stable, with no recent (1 month or less) inpatient admission for acute medical or surgical issues * baseline physical activity is kept stable * pain and antispasticity medications dose are kept stable * subjects are legally able to make their own health care decisions exclusion criteria: * associated lower motor neuron/peripheral nerve injury in the c1-c6 levels * presence of pacemaker * presence of cancer * history of seizures * women who are pregnant
evaluation of crestal bone loss around short dental implants as affected by two suprastructure materials

Conditions: Bone Loss

Summary: the aim of the study is to evaluate the crestal bone loss developed around short dental implants after using screw retained hybrid ceramic crowns when compare to screw retained lithium di silicate based ceramic crowns.

this study will be conducted on patients requiring single implant replacement in the posterior regions of the mandible, admitted to the outpatient clinic of fixed prosthodontics department, faculty of oral and dental medicine, cairo university. examination and diagnosis: 1. selection and examination of the patients according to inclusion and exclusion criteria. 2. preoperative cone beam computed tomography (cbct) to all patients. 3. primary impression will be taken to produce study cast. 4. taking a professional photo for the examined posterior area. 5. patients will be divided into two group: g1: short implants will be restored by screw retained hybrid ceramic crowns g2: short implants will be restored by screw retained lithium di silicate based ceramic crowns surgical procedures: * implants will be placed following standardized protocol. * after 4 months the patients re-attended for placement of healing abutments for about (10-14) days and prosthesis fabrication. data collection and post operative radio-logical assessment: -taking standardized digital peri-apical radio-graph by paralleling technique and film holding device for follow up at 12 months after crowns loading to evaluate crestal bone loss.

Eligibility criteria:
inclusion criteria: 1. patients within age group of ≥ 18. 2. there should be absence of any systemic diseases. 3. patients have missing simple posterior tooth 4. adequate interarch space. 5. inadequate residual bone height to place standard length implant. 6. patients with good oral hygiene. exclusion criteria: 1. a history that would complicate the outcome of the study, such as alcohol or drug dependency, smoking, poor health, or any other medical, physical or psychological reason that might affect the surgical procedure or the subsequent prosthodontics treatment and required follow-up. 2. heavy smokers. 3. poorly controlled diabetes mellitus. 4. patients on radiotherapy. 5. patients with temporomandibular disorders
a study of the effect of xmab®5871 in patients with systemic lupus erythematosus

Conditions: Systemic Lupus Erythematosus

Summary: the purpose of this study is to determine the ability of xmab5871 to maintain systemic lupus erythematosus (sle) disease activity improvement achieved by a brief course of disease-suppressing steroid therapy


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of sle as defined by the acr criteria * patients have a history of a (+) ana, (+) ena or a (+) anti-dsdna serology documented within one year prior to randomization * investigator has assessed the patient and in their judgment, the sle disease activity is not organ threatening * both investigator and patient agree that it is acceptable to discontinue their current immunosuppressant sle medications and receive a brief course of im steroid therapy * if patients are on oral steroids, they must be on the equivalent of ≤15 mg/day of prednisone to enter screening, and must be able to taper to ≤10 mg/day by randomization exclusion criteria: * history or evidence of a clinically unstable/uncontrolled disorder, condition or disease, other than sle that, in the opinion of the investigator would pose a risk to patient safety or interfere with the study evaluation, procedures or completion * patients who have organ threatening manifestations of sle including active class 3 or 4 lupus nephritis requiring induction or maintenance therapy or any other disorder for which stopping sle therapy is contraindicated * active cns lupus such as seizures or psychosis that in the opinion of the investigator would preclude participation * unstable hemolytic anemia or thrombocytopenia * patient is pregnant or breast feeding, or planning to become pregnant while participating in the study * use of any biologic therapy (including belimumab) within 6 months of randomization, or prior exposure to a monoclonal antibody directed to cd20 (such as rituximab) within 12 months of randomization
prediction of outcome of lupus nephritis

Conditions: Systemic Lupus Erythematosus

Summary: the purpose of this study is to clarify the mechanisms involved in the formation and glomerular deposition of immune complexes in lupus nephritis. the determination of an antibody pattern specific for systemic lupus erythematosus and lupus nephritis may also have a role in predicting disease progression in patients with systemic lupus erythematosus without renal impairment. as for the patients enrolled in the study, the determination of their antibody patterns may contribute to a more targeted and personalized treatment, allowing a prediction of disease progression and the introduction of early targeted treatments, in order to block the onset and/or progression of renal damage.

prospective multicenter study on the validity of levels of circulating antibodies to glomerular neo-autoantigens (alpha-enolase and annexin ai) and implantable antigens (anti-dna, histone, istone3, istone4, c1q) as a surrogate biomarker for the diagnosis of lupus nephritis. the study will involve the collection of serum from patients with lupus nephritis at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the titration of circulating autoantibodies. as a control the investigators will use the sera of patients with systemic lupus erythematosus without nephropathy, collected at the same time intervals. the investigators will also assess the antibody positivity in groups of patients with rheumatologic disease similar to lupus (rheumatoid arthritis) and in patients with autoimmune nephropathy without extrarenal clinical signs. regarding patients with systemic lupus erythematosus the investigators will collect sera of both incident and prevalent patients in order to monitor changes in antibody levels in conjunction with the development of renal disease. clinical tests (renal function, complete blood count, c reactive protein (crp), ana, native dna (ndna), urine analysis) will be performed at 6, 12, 24 and 36 months and the surplus of blood samples will be used to create the serum bank of the study. samples will be collected in the pediatric nephrology of giannina gaslini children hospital, genoa (coordinator centre) and in 5 rheumatological (genoa, pisa, pavia, padova, brescia) and 6 nephrological (milan, genoa, parma, brescia, bologna and reggio emilia) italian adults departments .

Eligibility criteria:
inclusion criteria: * age between 4 and 65 years * diagnosis of lupus nephritis-systemic lupus erythematosus (systemic lupus erythematosus, rheumatoid arthritis and membranous nephropathy for controls) * informed consent exclusion criteria: * severe infections in place * malignancies of any current or history * chronic hepatitis b virus (hbv) or hepatitis c virus (hcv) positive * breast-feeding or pregnant * known hypersensitivity to drugs
a study of verutex (fusidic acid), eritex (erythromycin) and fisiogel in the management of tarceva-associated rash.

Conditions: Non-Small Cell Lung Cancer

Summary: this 3 arm study will compare the efficacy and safety of three different dermatological creams designed for prophylaxis of skin rash associated with tarceva treatment in patients with locally advanced or metastatic non-small cell lung cancer. eligible patients who have recently started tarceva treatment will be randomized to one of 3 groups, to receive daily treatment with verutex, eritex or fisiogel cream for 30 days, and the incidence and severity of skin rash will be assessed. the anticipated time on study treatment is \<3 months, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, \>=18 years of age; * locally advanced or metastatic non-small cell lung cancer (stage iiib/iv); * eligible to start treatment with tarceva, or receiving tarceva for \<=5 days. exclusion criteria: * presence of skin rash or other signs of skin toxicity; * treatment with any systemic or intranasal antibiotic within 7 days before randomization; * treatment with other topical formulation within 14 days before randomization; * other anticancer therapy in addition to tarceva.
sequential or concurrent chemoradiotherapy in patients with locoregionally advanced npc

Conditions: Nasopharyngeal Carcinoma

Summary: the purpose of this study is to compare the efficacy and safety of sequential chemoradiotherapy (induction chemotherapy + intensity-modulated radiotherapy +adjuvant chemotherapy) with induction chemotherapy plus concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma (npc), in order to confirm the value of sequential chemoradiotherapy in npc patients.

patients with non-keratinizing npc iii-iva (uicc/ajcc 8th edition) are randomly assigned to receive sequential chemoradiotherapy (induction chemotherapy + intensity-modulated radiotherapy + adjuvant chemotherapy) or induction chemotherapy plus concurrent chemoradiotherapy. intensity-modulated radiotherapy (imrt) is given as 2.2 gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4 gy to the primary tumor. the induction or adjuvant chemotherapy is given gemcitabine (1000 mg/m² d1,8) and cisplatin (25mg/m² d1-3) every 3 weeks for two cycles. the concurrent chemotherapy is given cisplatin 30 mg/m² every week concurrently with imrt. our primary endpoint is failure-free survival(ffs) and grade iii mucositis during radiation. secondary end points include overall survival (os), locoregional failure-free survival (lr-ffs), distant failure-free survival (d-ffs) rates and toxic effects. all efficacy analyses are conducted in the intention-to-treat population, and the safety population include only patients who receive their randomly assigned treatment.

Eligibility criteria:
inclusion criteria: * patients with newly histologically confirmed non-keratinizing (according to who histologically type) * tumor staged as iii-iva (according to the 8th ajcc edition). * satisfactory performance status: karnofsky scale (kps) ≥ 70. * age between 18 and 65 years old. * adequate marrow: neutrophil count ≥2000/μl, hemoglobin ≥90g/l and platelet count ≥100000/μl. * normal liver function test: alanine aminotransferase (alt), aspartate aminotransferase (ast) ≤ 1.5×upper limit of normal (uln) concomitant with alkaline phosphatase (alp) ≤ 2.5×uln, and bilirubin ≤ 1.5uln. * adequate renal function: creatinine clearance ≥60 ml/min. * patients must be informed of the investigational nature of this study and give written informed consent. exclusion criteria: * evidence of distant metastasis * prior chemotherapy, radiotherapy or surgery (except diagnostic) to primary tumor or nodes. * other previous or concomitant cancer. * pregnancy or lactation. * presence of an uncontrolled concomitant illness including, but not limited to, ongoing or active infection, immune deficiency, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or emotional disturbance.

Keywords: nasopharyngeal carcinoma concurrent chemoradiotherapy sequential chemoradiotherapy
evaluation of adverse long-term effects in young adult survivors of acute leukemia

Conditions: Leukemia, Myeloid, Acute; Acute Lymphoid Leukemia

Summary: taking into account the specificities of adolescent and young adult cancer patients led agencies (in particular the french national cancer institute inca, through the last cancer plan), to initiate projects targeting this population. acute leukemia is among the most common cancers in adolescents and young adults. recent therapeutic advances now allow hope for a cure in about 50% of this population. the issue of post-cancer is therefore of particular importance for young adults with cancer. our aim is to establish the health determinants in young adult leukemia survivors and to compare the frequency of these effects and their explanatory factors to the data collected in children or adolescent leukemia survivors program (lea). 90 patients followed up at the institut paoli-calmettes cancer center and nice university hospital have been identified and would be included in this study.collected data will include information on the initial disease and its treatments, physical sequelae (fertility, thyroid function, heart function, visual function, secondary tumors, viral infections, lung function, bone metabolism, iron metabolism, metabolic syndrome, osteonecrosis, alopecia ... ), quality of life, social and occupational integration and relationship with care system.


Eligibility criteria:
inclusion criteria: * young adult (18-40 years) leukemia survivor, in complete remission. * acute leukemia diagnosed since january 1980 . * patient affiliated to social security or beneficiary * signed informed consent prior to any screening procedures exclusion criteria: * emergency * patient unable to abide by the study protocol (for geographical, social or psychological reasons)
peri implant marginal bone height and bone density

Conditions: Implant Site Reaction

Summary: this study aims to evaluate the effect of mandibular implant supported removable overdenture on bone height and density and compare it with implant supported fixed overdenture in single mandibular overdenture.

in this study 10 patients will be selected following inclusion and exclusion criteria. in each group 5 patients (each patient will receive 6 implants) will be divided randomly into two groups. group i patients will receive mandibular implant supported removable overdenture, while group ii will receive mandibular implant supported fixed overdenture. all patients will be given the usual home care instructions about wearing and caring of dentures and opposing arch. regarding dentures, removal of them at night and cleaning with denture brush and mild soap will be required. measurements of bone height and bone density will be obtained by using cone beam computed tomography (cbct). measurements will be obtained at denture insertion, after 1 month and after 3 months.

Eligibility criteria:
inclusion criteria: * non-smoker patients * highly cooperative and motivated patients. * patients systemically free from any immunosuppressive diseases. exclusion criteria: * diabetic, hypertensive, cancer patients. * mandibular arch with thin knife edge, flat or flabby ridge, recent extractions and foreign bodies. * patients with temporo-mandibular joint disorders and bad oral habits.

Keywords: bone height bone density implant supported
umbilical cord blood mononuclear cells therapy in liver cirrhosis

Conditions: Liver Cirrhosis

Summary: this study is to evaluate the safety and efficacy of umbilical cord blood mononuclear cells transplantation in liver cirrhosis patients.

decompensated liver cirrhosis (lc), a life-threatening complication of chronic liver disease, is one of the major indications for liver transplantation. recently, umbilical cord blood mononuclear cells transfusion has been shown to lead to the regression of liver fibrosis in animal model. the investigators thus investigated the safety of the therapy with life signs like temperature, pulse, blood pressure, the incidence of hepatocellular carcinoma and mortality and so on. and the efficacy was evaluated with the measurement of alanine aminotransferase (alt), glutamic oxaloacetic transaminase (ast), total bilirubin (tbil), direct bilirubin (dbil), albumin (alb), cholinesterase (che), prothrombin time (pt) and child-pugh score.

Eligibility criteria:
inclusion criteria: * patients with hepatocirrhosis: according to the standard of child- pugh, liver functions to achieve class a or b patients, including c class patients but can achieve b class after treatment exclusion criteria: 1. patients with c class by child-pugh score 2. patients in the acute phase of severe hepatitis 3. patients have been diagnosed with cancer of the liver 4. patients with severe cardiopulmonary cerebral disease, and in the failure state 5. patients in highly allergic constitution 6. patients with moderately severe mental disease
patient stratification and treatment response prediction in neuropharmacotherapy using hybrid positron emmission tomography/magnetic resconance imaging (pet/mr)

Conditions: Major Depressive Disorder

Summary: selective serotonin reuptake inhibitors (ssris) raise serotonin (5-ht) in the synaptic cleft and are the current first line of pharmacological antidepressive treatment. yet, there is a missing link between this first molecular step in their mechanism of action and observed clinical improvement. we have determined to establish a framework combining genuine molecular and functional imaging, i.e. hybrid pharmaco-pet/mr imaging, of the human serotonergic system in order to predict antidepressant treatment response. objectives: 1. to predict antidepressant treatment response from data obtained using hybrid pet/mr with acute pharmacological challenge. 2. to discriminate healthy from depressed subjects using this paradigm. 3. to establish models connecting regional changes in occupancy of serotonin transporters (5-htt) following citalopram infusion, with changes in brain activation and connectivity of major resting-state hub networks. design: randomized, double-blind, placebo-controlled, cross-over mono-center study. materials and methods: 40 major depressed (mdd) and 40 healthy subjects will undergo 2 pet/mr scans on a 3t siemens mmr biograph scanner: 1. challenge with citalopram 8mg 2. placebo (saline). after structural imaging, functional mri will be continuously acquired. \[11c\]dasb will be applied using a bolus + constant infusion paradigm to probe 5-htt binding potentials and monitor 5-htt occupancy with drug challenge, applied after 70min, in a single session. scanning will be terminated 80min after challenge. mdd patients will receive subsequent escitalopram treatment with repeated evaluation of response for 3 months.


Eligibility criteria:
inclusion criteria: * general health based on medical history, physical examination and structured clinical interview for dsm-iv (scid) * ham-d≥18 (patients) * willingness and competence to sign the informed consent form * age 18 to 55 years exclusion criteria: * any medical, psychiatric or neurological illness (other than mdd) * current or former psychopharmacological treatment * current or former substance abuse * pregnancy * any implant or stainless steel graft or any other contraindications for mri * failure to comply with the study protocol or to follow the instructions of the investigating team * participation in studies involving radiation exposure in the past 10 years. * body mass index \ 30
sensing-ai cohort for long covid patients

Conditions: Post-acute COVID-19 Syndrome

Summary: the prospective study will focus on the collection of biometric and psychometric data from a limited population for 1 month with the aim of complementing the sensing-ai retrospective cohort.

the stratification of the risk of complications related to persistent covid symptoms both physiological and psychological in a personalized way would optimize the cost-effectiveness model for the management of these patients. similarly, the early detection of complications associated with persistent covid in patients belonging to vulnerable groups would improve care times and, therefore, the patient's prognosis. the primary objective of this study is to complement the sensing-ai cohort with biometric and psychometric data prospectively gathered from patients diagnosed with long covid in the last year to drive the generation of ai-based risk prediction and stratification models.

Eligibility criteria:
inclusion criteria: * legal adults * with a long covid-19 diagnose in the last year * reporting any of these symptoms: * fatigue * dyspnea * shortness of breath * anxiety * stress * depression * conduct disorder * sleep disorder exclusion criteria: * hospital admission during follow-up due to pathology not related to covid-19 * patients without digital literacy or who cannot use the mobile application. * known severe psychiatric illness or cognitive impairment * being pregnant (or suspected to be pregnant) * discharged after hospital admission due to covid-19

Keywords: covid-19 syndrome prospective study artificial intelligence mental health
efficacy of new alcohol free mouthrinses

Conditions: Gum Disease

Summary: background to evaluate the efficacy of two alcohol-free antimicrobial mouthrinses in reducing plaque and gingivitis compared to an alcohol-containing rinse and toothbrushing alone. methods 160 healthy volunteers were enrolled in the parallel-design examiner-blind study. after screening and stratification by sex and papillary bleeding index (pbi), participants were randomly and equally assigned to four groups: (1) toothbrushing + rinsing (0.06% chx + 0.025% naf, alcohol-containing rinse, corsodyl® daily defence mouthwash; positive control); (2) toothbrushing + rinsing (0.06% chx + 0.025% naf, alcohol-free experimental rinse); (3) toothbrushing + rinsing (0.06% chx + 0.03% cpc + 0.025% naf, alcohol-free experimental rinse); (4) toothbrushing alone (negative control). at baseline, quigley-hein plaque index (qhi), the modified proximal plaque index (mppi), and pbi were recorded. all subjects were advised to brush their teeth as usual during the eight weeks study period. additionally, groups 1-3 were instructed to rinse twice daily (30 sec. each). all participants used dr. best multi aktiv toothpaste and dr. best plus toothbrush (medium stiffness). eight weeks after baseline, indices were recorded again. anova with bonferroni adjustment was used for statistical analysis.


Eligibility criteria:
inclusion criteria: * participants between 18 and 65 years * no severe periodontitis * informed consent exclusion criteria: * handicapped participants * allergies against mouth rinses